Statement of Changes in Beneficial Ownership (4)

FORM 4

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL

OMB Number:

3235-0287

Estimated average burden
hours per response...

0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * YANCOPOULOS GEORGE	2. Issuer Name and Ticker or Trading Symbol REGENERON PHARMACEUTICALS, INC. [ REGN ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director                    _____ 10% Owner __X__ Officer (give title below)    _____ Other (specify below) President and Chief Scientific
(Last)          (First)          (Middle) 777 OLD SAW MILL RIVER ROAD	3. Date of Earliest Transaction (MM/DD/YYYY) 3/9/2020
(Street) TARRYTOWN, NY 10591 (City)        (State)        (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								57465	I	by 2018 GRAT
Common Stock								500000	I	by 2019 GRAT

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (right to buy)	$30.63	3/9/2020		M (1)			96736	(2)	12/14/2020	Common Stock	96736	$0.0	150000	D
Non-Qualified Stock Option (right to buy)	$30.63	3/9/2020		M (1)			150000	(2)	12/14/2020	Common Stock	150000	$0.0	0 (3)	D

Explanation of Responses:
(1)	Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
(2)	With respect to 96,736 underlying shares, the option award vested in four equal annual installments, commencing one year after the date of grant; and with respect to 150,000 underlying shares, the option became exercisable on December 31, 2013, based upon the satisfaction by the Company of certain performance criteria during the period ended December 31, 2013.
(3)	Form two of two

Reporting Owners
Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
YANCOPOULOS GEORGE 777 OLD SAW MILL RIVER ROAD TARRYTOWN, NY 10591	X		President and Chief Scientific

Signatures
/s/**George D. Yancopoulos		3/11/2020
**Signature of Reporting Person		Date